The Estée Lauder Companies (ELC) has partnered with biotechnology company Serpin Pharma to explore longevity skin care innovations.
The Clinique and MAC-owner will tap the US-based biotech’s research on the efficacy of mitigating harmful inflammation and enhancing cell resiliency.
The two companies are investigating how this technology, which leverages the body’s innate immune response, can be harnessed to address skin irritation, ageing and sensitivity.
“This novel technology will advance our transformative innovation agenda by pushing the boundaries of breakthrough scientific discovery,” said Carl Haney, Executive VP Global Innovation and Research and Development at the Estée Lauder Companies.
“In partnership with Serpin Pharma, we are exploring powerful new biological pathways and cutting-edge biotech ingredients to rapidly mitigate visible skin irritation and sensitivity for our prestige beauty consumers worldwide.”
The partnership builds on ELC’s previous investments in longevity science, biotechnology and fermentation.
ELC said it “reinforces” its commitment to creating “transformative product innovation to deliver fast-to-market, on-trend innovation across in-demand subcategories and benefits”.
It also forms part of ELC’s newly unveiled Beauty Reimagined strategic vision, which aims to help the company return to profitability.
“Serpin Pharma was founded on the principles of biomimicry and how nature solves for signs of trauma and injury,” added Cohava Gelber, founder, Executive Chairperson and CEO of Serpin Pharma.
“We are taking a novel approach by tapping into the body’s innate mechanism for resolving inflammation.
“We are proud to partner with ELC to explore how our powerful biotechnology can be applied to cosmetics and skin care.”